Table 1. Baseline Characteristics.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| SOX (n = 288) | FOLFOX (n = 283) | |
| Age, y | ||
| Median (range) | 61 (24-78) | 62 (24-80) |
| <60 | 120 (41.7) | 120 (42.4) |
| ≥60 | 168 (58.3) | 163 (57.6) |
| Sex | ||
| Male | 197 (68.4) | 209 (73.9) |
| Female | 91 (31.6) | 74 (26.1) |
| Eastern Cooperative Oncology Group status | ||
| 0 | 155 (53.8) | 146 (51.6) |
| 1 | 123 (42.7) | 132 (46.6) |
| 2 | 10 (3.5) | 5 (1.8) |
| Primary tumor location | ||
| Upper | 59 (20.5) | 40 (14.1) |
| Middle | 58 (20.1) | 65 (23.0) |
| Lower | 152 (52.8) | 160 (56.5) |
| Diffuse type | 19 (6.6) | 18 (6.4) |
Abbreviations: FOLFOX, fluorouracil, leucovorin and oxaliplatin; SOX, S-1 and oxaliplatin.